OBJECTIVES: To conduct the budget impact analysis of Formoterol Easyhaler, which allowed to determine the net economic effect of the budget impact in regards of replacement of one medicine to another. METHODS: Information search was conducted in the public domain. Pharmacoeconomic analysis method – budget impact and direct cost analysis were performed. RESULTS: In this study, given the pharmacoeconomic evaluation of drugs Formoterol Easyhaler, Oxis Turbuhaler, Foradil Aerolizer and Atimos. The study had a time horizon of one year. The daily dose of formoterol was 24 mcg. Cost analysis was conducted on the cost of basic pharmacotherapy, compensation costs for treatment of exacerbations, compensation costs for side effects and adverse reactions. The total direct cost per patient with asthma amounted to 1 262, 17$ to the Easyhaler group, 1 581, 83$ to the Turbuhaler group, 1 498,95 and 1 499,99 to the Foradil (30 and 60 doses), and 1 705, 06$ to the Atimos. The selection of budget impact method of pharmacoeconomic analysis was determined by the advantages of Formoterol Easyhaler in terms of its efficiency and lower value of total direct costs. In the present study, based on the results of the “cost analysis” it was revealed that the replacement formoterol of Oxis Turbuhaler, Foradil Aerolizer (30 and 60 doses) and Atimos on Easyhaler saved per patient respectively 319,66$, 236,78$ (187, 82$ for 60 doses) and 442,89$ for the health care system budget. CONCLUSIONS: The budget impact analysis results obtained in this Formoterol Easyhaler versus others drugs of formoterol comparative study demonstrated that Easyhaler therapy resulted in budget saving.